These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 28592156)
21. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214 [TBL] [Abstract][Full Text] [Related]
22. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748 [TBL] [Abstract][Full Text] [Related]
23. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure. Rajkumar SV; Bergsagel PL; Kumar S Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241 [TBL] [Abstract][Full Text] [Related]
24. State of the science in smoldering myeloma: Should we be treating in the clinic? Hill E; Dew A; Kazandjian D Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611 [TBL] [Abstract][Full Text] [Related]
25. Smoldering multiple myeloma: Reviewing the rationale for intervention. Gertz M Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298 [TBL] [Abstract][Full Text] [Related]
26. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311 [TBL] [Abstract][Full Text] [Related]
27. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821 [TBL] [Abstract][Full Text] [Related]
28. The Role of Early Intervention in High-Risk Smoldering Myeloma. Joseph NS; Dhodapkar MV; Lonial S Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141 [TBL] [Abstract][Full Text] [Related]
30. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289 [TBL] [Abstract][Full Text] [Related]
31. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628 [TBL] [Abstract][Full Text] [Related]
32. Smoldering multiple myeloma: when to observe and when to treat? Mateos MV; San Miguel JF Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213 [TBL] [Abstract][Full Text] [Related]
33. Smoldering multiple myeloma 40 years later: a story of unintended disease. Yavorkovsky LL Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658 [No Abstract] [Full Text] [Related]
34. The Difficulty in Defining the True High-Risk Smoldering Myeloma. Weinhold N; Rasche L Clin Cancer Res; 2024 Oct; 30(19):4263-4265. PubMed ID: 39047171 [TBL] [Abstract][Full Text] [Related]
35. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. Fonseca R; Gonzalez-Velez M Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32207672 [TBL] [Abstract][Full Text] [Related]
36. Smoldering Myeloma Treatment: Who, What, and When. Mejia Saldarriaga M; Rossi A Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of smoldering multiple myeloma based on nationwide screening. Thorsteinsdóttir S; Gíslason GK; Aspelund T; Rögnvaldsson S; Óskarsson JÞ; Sigurðardóttir GÁ; Þórðardóttir ÁR; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Eyþórsson E; Jónsson Á; Berlanga O; Hultcrantz M; Durie BGM; Löve TJ; Harding S; Landgren O; Kristinsson SY Nat Med; 2023 Feb; 29(2):467-472. PubMed ID: 36747117 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic Advances in the Management of Smoldering Myeloma. Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112 [TBL] [Abstract][Full Text] [Related]
40. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J Med Clin (Barc); 2017 Jun; 148(11):517-523. PubMed ID: 28341370 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]